Review decision - January 2011
TA130 is currently under review. Further information about this review can be found on the Rheumatoid arthritis - adalimumab, etanercept, infliximab (TA130), certolizumab pegol (TA186) and golimumab (TA225 part review) - review [ID537] appraisals in development page.
Review of NICE Technology Appraisal Guidance No. 186 - Certolizumab pegol for the treatment of rheumatoid arthritis and No. 130 - Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
The Institute was proposing that a review of the existing guidance should be should be combined with the review of the current related technology appraisal of 'golimumab for the treatment of rheumatoid arthritis after the failure of disease modifying anti-rheumatic drugs' (expected publication date March 2011) and, as such, planned into the appraisal work programme.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. Given the developments in the field of rheumatoid arthritis since the publication of the aforementioned appraisals it was agreed that a review of these guidances would be appropriate.
After consideration of all of the comments (attached as appendix A), the Institute's Guidance Executive has decided that a review of the original guidance should be planned into the NICE work programme.
This page was last updated: 27 July 2012